2014.1-3a.Comment

                                                                                                 article in PDF
Our Dermatol Online 2014; 5(1): 18
Date of submission:  26.12.2014 / acceptance: 06.01.2014
Conflicts of interest: None
 
PSORIASIS UNCOVERED – COMORBID CONDITIONS WITH SPECIAL REFERENCE TO METABOLIC SYNDROME
by

Belliappa Pemmanda Raju, Umashankar Nagaraju

COMMENT:

Dr Rania Mounir Abdel Hay

Department of Dermatology, Faculty of Medicine, Cairo University, Egypt
E-mail: omleila2@yahoo.com 

 
Very interesting article, we should take care that the management of psoriasis should be shifted towards comprehensive disease management.
– Obesity may increase risk of liver and renal toxicity to Methotrexate and cyclosporine,
– Obesity may decrease the short-term clinical response to all systemic treatment,
– Decreasing body weight improves the response of obese patients to low dose cyclosporine therapy,
– Drugs indicated in co morbidities may exacerbate psoriasis; e.g ACEI, anticoagulants, diuretics, B blockers, and psycholeptics.
Drugs used to treat psoriasis can aggravate metabolic syndrome and co morbidities; e.g Cyclosporine may lead to hypertension, or impairment of kidneys, also Acitretine may change glucose tolerance, induce hyperlipidaemia or hepatopathy, also methotrexate may have hepatopathic effects.


CONTENT

SERVICES

Other Resources

Our Dermatology Online

Home
Current Issue
All Issues
Instruction for authors
Submit Manuscripts
Ethics in Publishing
For Reviewers
Readers
About
Editors & Publishers 
Statistics
Copyright
Contact Us